Tumor-promoting versus tumor-antagonizing roles of γδ T cells in cancer immunotherapy: Results from a prospective phase I/II trial

Journal of Immunotherapy

Volumn 35, Issue 2, 2012, Pages 205-213

  Kunzmann, Volker ^a,b   Smetak, Manfred ^d   Kimmel, Brigitte ^a   Weigang Koehler, Karin ^d   Goebeler, Mariele ^b   Birkmann, Josef ^d   Becker, Jürgen ^c   Schmidt Wolf, Ingo G H ^e   Einsele, Hermann ^a   Wilhelm, Martin ^d  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b Comprehensive Cancer Center Mainfranken ^*  (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d KLINIKUM NÜRNBERG   (Germany)

^e UNIVERSITY OF BONN   (Germany)

Author keywords

T cells; IL 2; immunotherapy; VEGF; zoledronic acid

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; VASCULOTROPIN; ZOLEDRONIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; FEMALE; FEVER; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; IN VIVO STUDY; KIDNEY CARCINOMA; LOW DRUG DOSE; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN TARGETING; SOLID TUMOR; T LYMPHOCYTE; TUMOR PROMOTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CELL SEPARATION; CYTOKINES; DIPHOSPHONATES; FEMALE; FLOW CYTOMETRY; HUMANS; IMIDAZOLES; INTERLEUKIN-2; KIDNEY NEOPLASMS; LEUKEMIA, MYELOID, ACUTE; MALE; MELANOMA; MIDDLE AGED; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTES;

EID: 84856878387     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318245bb1e     Document Type: Article

References (42)

1. Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: Recommendations of an international expert panel. Ann Oncol. 2008;19: 420-432.
2. Bedard PL, Body JJ, Piccart-Gebhart MJ. Sowing the soil for cure? Results of the ABCSG-12 trial open a new chapter in the evolving adjuvant bisphosphonate story in early breast cancer. J Clin Oncol. 2009;27:4043-4046.
3. Kunzmann V, Bauer E, Wilhelm M. Gamma/delta T-cell stimulation by pamidronate. N Engl J Med. 1999;340:737-738.
4. Kunzmann V, Bauer E, Feurle J, et al. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood. 2000;96:384-392. (Pubitemid 30463353)
5. Jagdev SP, Coleman RE, Shipman CM, et al. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: Evidence for synergy with paclitaxel. Br J Cancer. 2001;84: 1126-1134. (Pubitemid 32448513)
6. Winter MC, Holen I, Coleman RE. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev. 2008;34:453-475.
7. Croucher PI, De Hendrik R, Perry MJ, et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: Evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J BoneMiner Res. 2003;18:482-492. (Pubitemid 36241065)
8. Hiraga T, Williams PJ, Ueda A, et al. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res. 2004;10:4559-4567. (Pubitemid 38878900)
9. Santini D, Vincenzi B, Galluzzo S, et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res. 2007;13:4482-4486. (Pubitemid 47219717)
10. Aft R, Naughton M, Trinkaus K, et al. Effect of zoedronic acid on disseminated tumour cell in women with locally advanced breast cancer: An open label, randomised, phase 2 trial. Lancet Oncol. 2010;11:421-428.
11. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360:679-691.
12. Morgan G, Davies F, Gregory W, et al. Evaluating the effects of zoledronic acid (ZOL) on overall survival (OS) in patients (Pts) with multiple myeloma (MM): Results of the Medical Research Council (MRC) Myeloma IX study. J Clin Oncol (Meeting Abstracts). 2010;28:80-81.
13. Chlebowski RT, Chen Z, Cauley JA, et al. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol. 2010;28:3582-3590.
14. Rennert G, Pinchev M, Rennert HS. Use of bisphosponates and risk of postmenopausal breast cancer. J Clin Oncol. 2010; 28:3577-3581.
15. Rosenberg SA, Dudley ME, Restifo NP. Cancer immunotherapy. N Engl J Med. 2008;359:1072-1075.
16. Kunzmann V, Wilhelm M. Anti-lymphoma effect of gammadelta T cells. Leuk Lymphoma. 2005;46:671-680.
17. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol. 2001; 2:293-299. (Pubitemid 33706339)
18. Girardi M, Oppenheim DE, Steele CR, et al. Regulation of cutaneous malignancy by gammadelta T cells. Science. 2001; 294:605-609. (Pubitemid 32999559)
19. Sicard H, Al Saati T, Delsol G, et al. Synthetic phosphoantigens enhance human Vgamma9Vdelta2 T lymphocytes killing of non-Hodgkin's B lymphoma. Mol Med. 2001;7:711-722. (Pubitemid 33070985)
20. Lozupone F, Pende D, Burgio VL, et al. Effect of human natural killer and gammadelta T cells on the growth of human autologous melanoma xenografts in SCID mice. Cancer Res. 2004;64:378-385. (Pubitemid 38114121)
21. Kabelitz D, Wesch D, Pitters E, et al. Characterization of tumor reactivity of human V gamma 9V delta 2 gamma delta T cells in vitro and in SCID mice in vivo. J Immunol. 2004; 173:6767-6776. (Pubitemid 39541063)
22. Choudhary A, Davodeau F, Moreau A, et al. Selective lysis of autologous tumor cells by recurrent gamma delta tumorinfiltrating lymphocytes from renal carcinoma. J Immunol. 1995;154:3932-3940.
23. Dolstra H, Fredrix H, van der Meer A, et al. TCR gamma delta cytotoxic T lymphocytes expressing the killer cell-inhibitory receptor p58.2 (CD158b) selectively lyse acute myeloid leukemia cells. Bone Marrow Transplant. 2001;27:1087-1093. (Pubitemid 32591194)
24. Wilhelm M, Kunzmann V, Eckstein S, et al. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood. 2003;102:200-206. (Pubitemid 36759655)
25. Dieli F, Vermijlen D, Fulfaro F, et al. Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res. 2007;67:7450-7457. (Pubitemid 47206575)
26. Kobayashi H, Tanaka Y, Yagi J, et al. Safety profile and antitumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: A pilot study. Cancer Immunol Immunother. 2007;56:469-476. (Pubitemid 46204533)
27. Gober HJ, Kistowska M, Angman L, et al. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med. 2003;197:163-168. (Pubitemid 36152311)
28. Hayday AC. Gammadelta cells: A right time and a right place for a conserved third way of protection. Annu Rev Immunol. 2000;18:975-1026. (Pubitemid 30365402)
29. Hintz M, Reichenberg A, Altincicek B, et al. Identification of (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate as a major activator for human gammadelta T cells in Escherichia coli. FEBS Lett. 2001;509:317-322. (Pubitemid 34015963)
30. Espinosa E, Belmant C, Pont F, et al. Chemical synthesis and biological activity of bromohydrin pyrophosphate, a potent stimulator of human gamma delta T cells. J Biol Chem. 2001; 276:18337-18344.
31. Dieli F, Gebbia N, Poccia F, et al. Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood. 2003;102:2310-2311. (Pubitemid 37122416)
32. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
33. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21:4642-4649. (Pubitemid 46594039)
34. Thall PF, Simon R, Ellenberg SS. A two-stage design for choosing among several experimental treatments and a control in clinical trials. Biometrics. 1989;45:537-547. (Pubitemid 19165264)
35. Buyse M, Squifflet P, Lange BJ, et al. Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. Blood. 2011;117:7007-7013.
36. Uchida R, Ashihara E, Sato K, et al. Gamma delta T cells kill myeloma cells by sensing mevalonate metabolites and ICAM-1 molecules on cell surface. Biochem Biophys Res Commun. 2007; 354:613-618. (Pubitemid 46161370)
37. Lanca T, Correia DV, Moita CF, et al. The MHC class Ib protein ULBP1 is a nonredundant determinant of leukemia/ lymphoma susceptibility to gammadelta T-cell cytotoxicity. Blood. 2010;115:2407-2411.
38. Ugurel S, Rappl G, Tilgen W, et al. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol. 2001;19:577-583. (Pubitemid 32112873)
39. Duncan TJ, Al-Attar A, Rolland P, et al. Vascular endothelial growth factor expression in ovarian cancer: A model for targeted use of novel therapies? Clin Cancer Res. 2008;14:3030-3035.
40. Sabatino M, Kim-Schulze S, Panelli MC, et al. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol. 2009; 27:2645-2652.
41. Coscia M, Quaglino E, Iezzi M, et al. Zoledronic acid repolarizes tumor-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med. 2010;14:2803-2815.
42. Wakita D, Sumida K, Iwakura Y, et al. Tumor-infiltrating IL- 17-producing gammadelta T cells support the progression of tumor by promoting angiogenesis. Eur J Immunol. 2010;40: 1927-1937.